Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Status:
Recruiting
Trial end date:
2023-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of resection plus
neoadjuvant hepatic arterial infusion chemotherapy (HAIC) compared with resection alone in
patients with resectable hepatocellular carcinoma beyond Milan criteria.